An Open Letter in Response to the FDA’s Public Comment Request on the Clinical Data Summary Report Pilot

An Open Letter in Response to the FDA’s Public Comment Request on the Clinical Data Summary Report Pilot.

In January 2018, the FDA announced a pilot aimed at enhancing the transparency of the Agency's drug approval process and decisions...

Click here to find out more.

Image Credit: pixabay.